Cargando…
Gain of chromosome arm 17q is associated with unfavourable prognosis in neuroblastoma, but does not involve mutations in the somatostatin receptor 2 (SSTR2) gene at 17q24
Deletion of chromosome arm 1p and amplification of the MYCN oncogene are well-recognized genetic alterations in neuroblastoma cells. Recently, another alteration has been reported; gain of the distal part of chromosome arm 17q. In this study 48 neuroblastoma tumours were successfully analysed for 17...
Autores principales: | Abel, F, Ejeskär, K, Kogner, P, Martinsson, T |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1999
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362984/ https://www.ncbi.nlm.nih.gov/pubmed/10604740 http://dx.doi.org/10.1038/sj.bjc.6692231 |
Ejemplares similares
-
The loss of DLG2 isoform 7/8, but not isoform 2, is critical in advanced staged neuroblastoma
por: Keane, Simon, et al.
Publicado: (2021) -
Aggressive neuroblastomas have high p110alpha but low p110delta and p55alpha/p50alpha protein levels compared to low stage neuroblastomas
por: Fransson, Susanne, et al.
Publicado: (2013) -
Genetic and epigenetic changes in the common 1p36 deletion in neuroblastoma tumours
por: Carén, H, et al.
Publicado: (2007) -
Coexpression of human somatostatin receptor-2 (SSTR2) and SSTR3 modulates antiproliferative signaling and apoptosis
por: War, Sajad A, et al.
Publicado: (2012) -
Clinical Significance of Somatostatin Receptor (SSTR) 2 in Meningioma
por: Wu, Wei, et al.
Publicado: (2020)